BioSpace News Archive

BioInvent International AB announced that the Annual Report for 2020 is published and available at the company’s website, www.bioinvent.com.

Atopic dermatitis is the most common type of eczema. Moderate to severe atopic dermatitis is a chronic and incurable condition, severely disrupting patients’ quality of life

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the 20th Annual Needham Virtual Healthcare Conference.

Abby is the next generation chemiluminescence Western protein analyzer and Stellar modules set the standard for fluorescence sensitivity

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it plans to formalize discussions with the U.S. Food and Drug Administration (“FDA”) by filing an End-of-Phase 2 meeting request (EOP2) based on the completion of the Phase 2b part of its Phase 2b/3 COVID-19 trial (the “Study”) of NP-120

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey , the Company’s President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference.

The U.S. Food and Drug Administration (FDA) has granted Donisi ‘s revolutionary contact-free multiparameter measurement system de novo clearance, making Donisi the first to bring this innovative technology to the medical market.

Sutro Biopharma, Inc. , today announced that Chief Executive Officer, Bill Newell , will present at two upcoming investor conferences

Volastra Therapeutics Co-founder Samuel Bakhoum to Deliver Plenary Presentation at American Association for Cancer Research Annual Meeting 2021 Dr. Bakhoum will present on the critical role of chromosomal instability in cancer metastasis.

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, April 29, 2021, the Company will release financial results for the fourth quarter of fiscal 2021. The Company will host a conference call to discuss the results on Thursday, April 29, 2021 at 8:00 a.m. ET.